Zacks Rating on Globus Medical (GMED)

Globus Medical (GMED) : 5 brokerage houses believe that Globus Medical (GMED) is a Strong Buy at current levels. 5 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Globus Medical (GMED). Zacks Investment Research suggests a Hold with a rank of 3. 1 analysts perceive the stock to be overvalued at the existing levels, hence their call is to Sell the stock.The median of all the 11 Wall Street Analysts endorse the stock as a Buy with a rating of 2.18.

Globus Medical (GMED) stock is expected to deviate a maximum of $3.24 from the average target price of $26.75 for the short term period. 8 Street Experts have initiated coverage on the stock with the most promising target being $33 and the most muted being $23.


Globus Medical, Inc. has lost 0.17% in the last five trading days and dropped 12.15% in the last 4 weeks. Globus Medical, Inc. has dropped 3.51% during the last 3-month period . Year-to-Date the stock performance stands at -17.9%. Globus Medical (NYSE:GMED): On Tuesdays trading session , Opening price of the stock was $22.89 with an intraday high of $23.23. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $22.78. However, the stock managed to close at $22.84, a loss of 0.22% for the day. On the previous day, the stock had closed at $22.89. The total traded volume of the day was 313,980 shares.

Globus Medical, Inc. is a medical device company. The Company is focused on developing products for patients with musculoskeletal disorders and spine disorders. Its products consist of two categories: Innovative Fusion and Disruptive Technologies. Innovative Fusion products comprise fusion products to treat various spinal disorders for the entire spine and can be used in various surgical approaches. Disruptive Technologies represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders. The Companys portfolio of Disruptive Technology products includes products that allow for minimally invasive surgical (MIS) techniques, as well as treatment alternatives, including motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous process spacer products, and biomaterials technologies, as well as interventional pain management solutions.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.